Wanjia Group Holdings Limited (HKG:0401)
0.0740
-0.0040 (-5.13%)
Sep 15, 2025, 3:58 PM HKT
Wanjia Group Holdings Revenue
In the fiscal year ending March 31, 2025, Wanjia Group Holdings had annual revenue of 161.69M HKD, down -10.71%. Wanjia Group Holdings had revenue of 78.00M in the half year ending March 31, 2025, a decrease of -6.65%.
Revenue
161.69M
Revenue Growth
-10.71%
P/S Ratio
0.26
Revenue / Employee
898.29K
Employees
180
Market Cap
41.46M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 161.69M | -19.40M | -10.71% |
Mar 31, 2024 | 181.09M | 7.39M | 4.25% |
Mar 31, 2023 | 173.70M | 18.88M | 12.19% |
Mar 31, 2022 | 154.82M | 40.74M | 35.71% |
Mar 31, 2021 | 114.09M | 17.11M | 17.64% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
JD Health International | 71.34B |
Hansoh Pharmaceutical Group Company | 14.45B |
Innovent Biologics | 12.52B |
Sino Biopharmaceutical | 33.49B |
WuXi Biologics | 21.98B |
Akeso | 2.75B |
CSPC Pharmaceutical Group | 28.49B |